STOCK TITAN

Radiopharm RAD101 shows 93.5% interim MRI agreement

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Radiopharm Theranostics Limited (RADX) presented interim Phase 2b imaging results for RAD101 in suspected recurrent brain metastases following radiotherapy. 18F-RAD101 PET/CT showed 93.5% patient-level agreement with contrast-enhanced MRI for all-lesion detection. Sensitivity was 85.7% among 16 participants evaluable against the reference standard at interim analysis. The study enrolled 32 participants; no treatment-emergent serious adverse events or clinically significant laboratory or ECG abnormalities were observed among the 32 dosed.

Radiopharm plans to report final analyses, including specificity and complete diagnostic follow-up, in Q1 2027. The company reported alignment with the U.S. FDA on a single, multicenter Phase 3 imaging trial and a partnership with Siemens Healthineers to manufacture and distribute RAD101 doses for that trial.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointIn Phase 2b, RAD101 had 93.5% patient-level agreement with MRI.

Negative

  • None.

Filing Explained

The Form F-3 now includes this clinical announcement; the report separately identifies RAD101’s FDA Fast Track designation.

A Form 6-K furnishes a foreign private issuer’s interim material information; this report incorporates its clinical announcement into Radiopharm’s Form F-3 registration statement, making the announcement part of that filing.

The announcement also reports that RAD101 has received FDA Fast Track Designation.

Patient-level agreement 93.5% 18F-RAD101 PET/CT versus contrast-enhanced MRI for all-lesion detection
Sensitivity 85.7% Interim analysis among 16 participants evaluable against the reference standard
Participants enrolled 32 participants Phase 2b imaging study
Participants evaluable 16 participants Interim sensitivity analysis against the reference standard
U.S. annual brain metastases diagnoses More than 300,000 patients Company-stated annual U.S. diagnoses
patient-level agreement medical
"high patient-level agreement between 18F-RAD101 PET/CT and contrast-enhanced MRI"
reference standard medical
"evaluable against the reference standard (histopathology or longitudinal MRI follow-up)"
Fast Track Designation regulatory
"RAD101 has received FDA Fast Track Designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
FASN-associated fatty acid metabolism technical
"images FASN-associated fatty acid metabolism in brain metastases"
18F-labelled fatty acid analogue medical
"RAD101 is an ¹⁸F-labelled fatty acid analogue"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RADX report for RAD101 in the Phase 2b study?

In the interim analysis, 18F-RAD101 PET/CT had 93.5% patient-level agreement with contrast-enhanced MRI for all-lesion detection. Sensitivity was 85.7% among 16 participants evaluable against the reference standard, defined as histopathology or longitudinal MRI follow-up.

When are RADX's remaining RAD101 results planned?

Radiopharm plans to report final analyses, including specificity and complete diagnostic performance on follow-up, in Q1 2027. The company also reported FDA alignment for a single, multicenter Phase 3 imaging trial evaluating RAD101 in patients with indeterminate brain metastases following radiotherapy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of November 2026

 

Commission File Number: 001-41621

 

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

 

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

 

RADIOPHARM THERANOSTICS LIMITED

 

EXPLANATORY NOTE

 

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on November 16, 2026 titled:

 

“RAD interim analysis at SNO26 on RAD101 Phase IIb data”  

 

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

 

This Form 6-K, including the exhibits hereto, is incorporated by reference into the registration statement of the Company on Form F-3 (File No. 333-292178) and forms part thereof to the extent not superseded by documents or reports subsequently filed by the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934. 

 

1

 

EXHIBITS

 

Exhibit
Number
  Description
99.1   RAD interim analysis at SNO26 on RAD101 Phase IIb data

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  RADIOPHARM THERANOSTICS LIMITED
     
Date: November 16, 2026 By: /s/ Amritha Sushil
    Amritha Sushil
    Company Secretary

 

3

 

Exhibit 99.1

 

ASX ANNOUNCEMENT
16 November 2026
 

 

Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting

 

Concordance between 18F-RAD101 PET and contrast-enhanced MRI (93.5% patient-level agreement); preliminary sensitivity of 85.7% against the reference standard

 

Favourable safety profile with no serious treatment-emergent adverse events observed in any of the 32 participants dosed

Final analyses including specificity and complete diagnostic performance on follow-up planned to be reported in Q1 2027

 

Recently announced alignment with the U.S. FDA for a single, multicenter Phase 3 imaging trial evaluating RAD101 in patients with indeterminate brain metastases following radiotherapy

 

Sydney, Australia– 16 November 2026 – Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that data from the Phase 2b imaging study of RAD101 in suspected recurrent brain metastases following radiotherapy were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, which took place from November 12-15, 2026 in Philadelphia, PA.

 

“We were honored to present these encouraging interim Phase 2b results at SNO before an audience of neuro-oncology experts who confront the challenge of distinguishing recurrent disease from treatment-related effects on a daily basis,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “For clinicians caring for patients with brain metastases, uncertainty in imaging can have profound implications for treatment decisions, making the need for more accurate diagnostic tools increasingly urgent. We believe the high concordance observed between RAD101 PET/CT and MRI, together with encouraging preliminary sensitivity data and a favorable safety profile, further supports RAD101’s potential to address this critical unmet need. Following our recent alignment with the U.S. FDA on a pivotal Phase 3 imaging study, we remain focused on advancing RAD101 toward a prospective regulatory submission and are actively engaging with potential strategic partners. We look forward to reporting additional diagnostics accuracy analyses as we continue to build the evidence supporting RAD101’s differentiated value.”

 

The Phase 2b, open-label, single-dose, single-arm, multicenter imaging study enrolled 32 participants who had suspected recurrence of previously irradiated brain metastases.

 

The primary endpoint was concordance with MRI, which had high patient-level agreement between 18F-RAD101 PET/CT and contrast-enhanced MRI at 93.5% for all-lesion detection. For the secondary endpoint, among the 16 participants evaluable against the reference standard (histopathology or longitudinal MRI follow-up) at the interim analysis, sensitivity was 85.7%.. No treatment-emergent serious adverse events or clinically significant laboratory or ECG abnormalities were observed. The company plans on reporting additional diagnostic accuracy data and complete diagnostic follow up in 2027.

 

RAD101 has received FDA Fast Track Designation to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease. The company has also announced a partnership with Siemens Healthineers, who will manufacture and distribute doses of 18F-labeled RAD101 to support the upcoming Phase 3 registrational trial in the U.S.

 

In the U.S. alone, there are more than 300,000 patients diagnosed annually with brain metastases. The incidence of Intracranial Metastatic Disease (IMD) continues to increase, in part, due to improvements in systemic therapy resulting in a more durable control of the tumors outside of the central nervous system. Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is the preferred method for imaging IMD, but has limitations, particularly in follow-up surveillance scans to optimise patient care.1 

 

 
1A hybrid [18F]fluoropivalate PET-multiparametric MRI to detect and characterise brain tumour metastases based on a permissive environment for monocarboxylate transport | European Journal of Nuclear Medicine and Molecular Imaging

 

Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889

 

 

ASX ANNOUNCEMENT
16 November 2026
 

 

About RAD101

 

RAD101 is an ¹⁸F-labelled fatty acid analogue that images FASN-associated fatty acid metabolism in brain metastases. (FASN) is a multi-enzyme protein that catalyses de novo fatty acid synthesis and is overexpressed in brain metastases from solid tumors. Targeting FASN activity may allow for the more accurate detection of cancer cells in the CNS, representing a clinically relevant method for the imaging of brain metastases. Positive data from the Imperial College London’s Phase 2a imaging trial of 18F-RAD101 in patients with brain metastases (both SRS pre-treated and treatment naïve patients) showed significant tumor uptake that was independent from the tumor of origin. The study further indicated that PET-MRI may provide non-invasive prediction of overall survival, warranting larger studies.

 

About Radiopharm Theranostics

 

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com

 

Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper.

 

For more information:

 

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

 

Anne Marie Fields

Precision AQ (Formerly Stern IR)

E: annemarie.fields@precisionaq.com

 

Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

 

Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889

 

 

Filing Exhibits & Attachments

1 document

Keep reading